Cytokine (TNF alpha) blocking for acute and chronic graft versus host disease (GVHD)

Cytokine (TNF alpha) blocking for acute and chronic graft versus host disease (GVHD) - Cytokine blocking for GVHD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003147

Enrollment

Registered

2010-02-12

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft versus host disease (GVHD)

Interventions

Etanercept 0.4-1.0mg/ kg/ time (max 25mg) Subcutaneous injection, total 8 weeks Twice/ first 4 weeks, once/ last 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients received hematopoietic stem cell transplantation. And who diagnosed as steroid refractory or dependence GVHD. Who cannot receive conventional therapies for GVHD because of poor organ functions. Refractory; No improvement by at least 6 days systemic steroid therapy. Dependence; Need for over 20mg/day times 6 weeks steroid therapy.

Exclusion criteria

Exclusion criteria: 1. sepsis, risk of sepsis 2. severe infection 3. active tuberculosis 4. anaphylactic episode of etanercept 5. demyelinating disease 6. congestive heart failure

Design outcomes

Primary

Measure	Time frame
Evaluation of clinical GVHD score and improvement of labolatory data between before with after therapy.	—

Countries

Japan

Contacts

Public ContactKajiwara Ryosuke

Yokohama city university hospital Pediatrics

kaji6485@yokohama-cu.ac.jp+81-45-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026